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Angiotensin-converting enzyme 2 (ACE2) is a
monocarboxypeptidase that degrades angiotensin II with
high efficiency leading to the formation of angiotensin-(1–7).
ACE2 within the kidneys is largely localized in tubular
epithelial cells and in glomerular epithelial cells. Decreased
glomerular expression of this enzyme coupled with increased
expression of ACE has been described in diabetic kidney
disease, both in mice and humans with type 2 diabetes.
Moreover, both ACE2 genetic ablation and pharmacological
ACE2 inhibition have been shown to increase albuminuria
and promote glomerular injury. Studies using recombinant
ACE2 have shown the ability of ACE2 to rapidly metabolize
Ang II in vivo and form the basis for future studies to examine
the potential of ACE2 amplification in the therapy of diabetic
kidney disease and cardiovascular disease.
Kidney International (2012) 81, 520–528; doi:10.1038/ki.2011.381;
published online 23 November 2011
KEYWORDS: angiotensin; diabetic nephropathy; renin–angiotensin system
Angiotensin-converting enzyme 2 (ACE2) is a type 1 integral
membrane protein that shares 42% homology with the
metalloprotease catalytic domains of ACE.1 Unlike ACE,
which consists of two catalytic domains, ACE2 contains only
a single active domain and consists of 805 amino acids.1–2
Other mammalian homologs of ACE such as collectrin
and, more recently, ACE3, have been described.3,4 ACE2,
however, is the only known homolog of ACE with enzymatic
activity.3 ACE3 seems to lack catalytic properties as a
zinc metalloprotease, and the presence of deletions and
insertions in the sequence suggests that in humans ACE3 is a
pseudogene.3
The catalytic mechanism of ACE2 closely resembles that of
ACE. It functions as a zinc metalloprotease owing to its
canonical HEXXH sequence (amino acids 374–378), it is
inhibited by EDTA, and it removes carboxy-terminal amino
acids from several peptides.1,2,5 Differences in substrate
specificity between ACE2 and ACE indicate that there are
differences in the substrate sites of ACE2 and testicular ACE.6
ACE2 functions as a monocarboxypeptidase by removing
single amino acids from the C terminus of its substrates,
whereas ACE functions predominantly as a peptidyl dipepti-
dase removing C-terminal dipeptides. ACE2 cleavage of
angiotensin II (Ang II) leads to the formation of Ang-(1–7),
whereas cleavage of Ang I leads to the formation of Ang-
(1–9).1,2,5 At least 11 peptides have been identified that are
completely or partially hydrolyzed by ACE2.5 ACE2 has the
highest catalytic efficiency for the degradation of Ang II. The
hydrolysis of apelin-13 has comparable kinetics to that of Ang
II.5 Other peptides that are hydrolyzed by ACE2 with high
efficiency include the opioid peptide dynorphin A, des-Arg
bradykinin, and ghrelin, a growth hormone secretagogue.5,7
ACE2 has a more widespread distribution in mammalian
tissues than originally thought. Tissues with high levels of
ACE2 include the kidneys, testes, intestines, and heart,
whereas relatively low levels of ACE2 mRNA have been
detected in numerous other tissues.1,2 ACE2 is preferentially a
tissue enzyme, and therefore is more likely to be involved in
the degradation of Ang II in chronic conditions associated
with overactivity of this peptide, such as diabetic nephrop-
athy. In this condition, ACE2 downregulation may cause
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excessive Ang II accumulation, particularly at the glomerular
level, leading to increased albuminuria and glomerular
damage.8
In this review, we will discuss Ang II degradation and the
role of ACE2 as a key enzyme in controlling the levels of this
peptide, as well as in the formation of Ang-(1–7). We will not
discuss other important actions of ACE2 related to cleavage
of other substrates such as apelin.9 We will also review recent
studies dealing with the expression of ACE2 within the
kidney and experimental rodent models of diabetic kidney
disease and human diabetic nephropathy.
ACE2 AND THE ANG II DEGRADING PATHWAY
The formation and degradation of Ang II is a complex
process that involves pathways other than those driven by
ACE and ACE2. ACE2 degrades Ang II leading to the
formation of Ang-(1–7); this peptide is degraded to Ang-
(1–5) by the action of ACE (Figure 1). Other pathways for
Ang II degradation, other than ACE2-driven hydrolysis,
include aminopeptidase A, which cleaves Ang II to form Ang-
(2–8), also known as Ang III.10 Aminopeptidase N can
subsequently convert Ang-(2–8) to Ang IV.10 Ang II can
also be degraded to Ang IV by the action of dipeptidyl-
aminopeptidase I–II. Another pathway of Ang II degradation
involves digestion by neprilysin, endopeptidases, and carboxy-
peptidases into small peptide fragments of unknown biolo-
gical function (Figure 1).11,12
There is overwhelming evidence that renin is the rate-
limiting step in the activation of Ang II via its control of
Ang I formation.13 For instance, changes in salt intake
modulate Ang II activity largely via changes in renin release
and circulating plasma renin activity. Little is known
regarding ACE2 activity changes elicited by physiological
perturbations such as dietary salt intake. If one views ACE2
as a counter-regulatory enzyme in the regulation of Ang II,
changes in ACE2 would be expected whenever ACE or Ang II
levels change (Figure 2). We will limit our analysis of changes
in ACE and ACE2 that may occur under physiological
conditions as a way to regulate Ang II levels, and for
simplicity we will ignore the potential concurrent changes in
several other pathways involved in Ang II degradation and
formation. It is important to emphasize that our foregoing
analysis in this regard is speculative and that data regarding
physiological changes in ACE2 is rather limited, and therefore
future studies are needed and may or may not support our
expectations.
To maintain Ang II at a steady-state level, the formation
driven by ACE and the degradation driven by ACE2 need to
be coordinated under physiological conditions (Figure 2).
When Ang II formation increases as a result of Ang I
formation, an increase in ACE would also be expected. In this
situation, one would anticipate that ACE2 would eventually
increase to foster Ang II degradation; otherwise, Ang II would
increase without a checkpoint. It is possible, however, that
the increase in ACE2 is delayed or does not match the
increase in ACE activity so that Ang II levels are kept elevated
transiently as in subjects on a low-salt diet. Conversely, if Ang
II formation decreases as in a high-salt diet, one would expect
a decrease in ACE, followed by a decrease in ACE2 (Figure 2).
To our knowledge, these basic questions, however, have not
been examined either directionally or temporally. Moreover,
studies should be conducted comparing the regulation of
ACE2 in the circulation, where the levels are generally low,
and at the tissue level where the levels are higher, particularly
in the kidneys. There is a need for studies addressing the
mechanism of any potential changes in ACE2 expression as to
whether they occur at the mRNA or protein level or during
any other posttranslational modifications. To date, we are
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Figure 1 |Angiotensin II (Ang II) degradation pathways. Schematic representation of the enzymes involved in the metabolism of Ang
peptides. Ang II is degraded by Angiotensin-converting enzyme 2 (ACE2) to form Ang-(1–7), which subsequently can be degraded by ACE
to form Ang-(1–5). Other pathways of Ang II degradation include aminopeptidase A to Ang-(2–8), dipeptidyl-aminopeptidase I–III to
Ang IV, and neprilysin and various peptidases to other small peptide products. Ang-(2–8) and Ang IV may also be reversibly interchanged
via aminopeptidase N.
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aware of only one study that shows that a physiological
manipulation, such as a high-salt diet, reduces ACE2 at the
mRNA and protein level in the heart.14
Overall, the concept of counter-regulation implies that
ACE2 changes in the same direction as ACE does under
physiological conditions. This way, changes in ACE2 could
compensate for changes in ACE in such a manner that Ang II
levels are attenuated. Under pathophysiological conditions, a
disassociation between the activities of the enzymes may
occur, leading to changes in opposite directions (Figure 2).
Discordance in the activity levels of these two enzymes (for
instance increased ACE, decreased ACE2) has been well
documented in diabetic models of kidney disease. For
instance, decreased ACE2 with increased ACE has been
found in glomeruli from diabetic mice.8 This combination
would foster Ang II accumulation that could contribute to
the development of disease.8 By contrast, if ACE was
decreased and ACE2 was increased, this would lead to
decreased Ang II in the chronic setting, which could be
renoprotective.15 The use of the ACE/ACE2 ratio to capture
changes in these enzymes is convenient.15–17 It is important
to emphasize, however, that the ratio may lead to misleading
conclusions because each enzyme is regulated independently.
The ratio is only a convenient way to portray a given pattern
of ACE and ACE2 expression particularly under pathophy-
siological conditions.
EVIDENCE THAT ACE2 EFFICIENTLY DEGRADES ANG II IN VIVO
In studies conducted on ACE2-null mice, Crackower et al.18
detected an increase in Ang I and II levels in kidneys and
hearts, in conjunction with increased Ang II levels in plasma
Although two other investigative groups did not find
differences in baseline circulating Ang II levels between
wild-type and ACE2-knockout mice, Gurley et al.19 reported
that plasma levels of Ang II were almost threefold higher in
ACE2-deficient mice than in control animals after an acute
intravenous infusion of Ang II.20 ACE2-null mice also
exhibited a more severe hypertension after chronic Ang II
infusion, which was associated with increased Ang II
accumulation in the kidney.19 Moreover, Shaltout et al.21
found that inhibition of ACE2 significantly slows the
conversion of Ang II to Ang-(1–7) in isolated sheep proximal
tubules but does not affect the metabolism of Ang I. These
studies suggest that ACE2 is an important pathway for the
metabolism of Ang II in vivo.
Human recombinant ACE2 (hrACE2) has been used
recently to study the degradation of Ang II in vivo and
in vitro.22 The cleavage of Ang II by hrACE2 was assessed
by incubation of Ang II with hrACE2 for 0, 30, and
60 min, followed by reverse-phase HPLC analysis.22 A
reduced Ang II peak was seen at 30 and 60 min, consistent
with a robust cleavage of Ang II by hrACE2. The
reaction products after 30 and 60 min of incubation with
hrACE2 showed an emerging peak, which corresponded to
the ACE2 product Ang-(1–7).22 In addition, a separate
shallow wide peak was observed, which represented another
breakdown product of Ang II, the single amino acid
phenylalanine.22
The effects of hrACE2 in vivo on the metabolism of Ang II
were assessed by measuring the levels of Ang II and Ang-
(1–7) following the administration of Ang II at pressor
doses.22 In C57BL/6J mice, the increase in blood pressure
triggered by Ang II infusion was completely prevented by the
administration of hrACE2. After administration of hrACE2,
plasma Ang II levels were reduced, whereas Ang-(1–7) levels
were increased (Figure 3). These findings in vivo replicate the
effect of hrACE2 in vitro and show the importance of ACE2
in the metabolism of Ang II.
The actions of ACE2 could result in the degradation of
Ang II, the corresponding increase in Ang-(1–7), or both.
However, despite the blockade of the Ang-(1–7) receptor with
A779, a Mas receptor blocker, the administration of hrACE2
still abrogated the blood pressure increase, caused by Ang II
infusion, to the same extent as in the absence of A779
(Figure 3).22 In addition, neither administration of A779 nor
Ang-(1–7) at pharmacological doses had an effect on the
blood pressure increase observed after Ang II infusion.22
Thus, during Ang II infusions, administration of hrACE2
lowers blood pressure by a mechanism independent of Ang-
(1–7). This blood pressure-lowering effect is attributable to
an increase in circulating ACE2 activity because ACE2
activity did not increase in the kidney or heart. Accordingly,
amplification of ACE2 activity at the tissue level should also
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Figure 2 |Angiotensin II (Ang II) regulation by angiotensin-
converting enzyme (ACE) and ACE2. Degradation pathways for
Ang II. In normal physiology, one would expect that to tightly
regulate Ang II, if ACE activity increases, there must be a
concomitant increase in ACE2 so that the rates of formation and
degradation remain equal. It should be noted that there is a
paucity of studies and the proposed changes are speculative. In
pathophysiological conditions, such as diabetic kidney disease,
discordance in the activity of these two enzymes has been shown.
This would affect the level of Ang II in ways that are maladaptive.
For instance, the combination of high ACE and low ACE2 would
result in an increase in Ang II, which would be detrimental (C) with
regard to disease progression. Another situation, where ACE
decreases and ACE2 increases, may prevent Ang II accumulation
and therefore be renoprotective (D).15
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have important effects that cannot be achieved by hrACE2
administration, which is restricted to increasing serum ACE2
activity only.
ANG II VS. ANG (1–7)
Although the findings above show the dominant effect of Ang
II over Ang-(1–7) on blood pressure control following
hrACE2 administration, one cannot exclude a role of Ang-
(1–7) in blood pressure control. Similarly, other biological
consequences of ACE2 may be related in part to enhanced
formation of Ang-(1–7). Consistent with the findings of
Wysocki et al.22, a study in 2K1C Goldblatt model of
hypertension found that Ang-(1–7) infusion did not attenuate
a rise in blood pressure.23 By contrast, a chronic blockade of
the Ang-(1–7) receptor with 7-D-Ala was shown to worsen the
hypertension observed in Goldblatt model rats.23 Moreover,
data by Lovren et al.24 suggest that some effects of ACE2
associated with an improvement of endothelial function in
cultured endothelial cells involve an Ang-(1–7)-dependent
pathway. Ang II-induced endothelial dysfunction was partially
diminished by ACE2 via an Ang-(1–7)-dependent mechanism
that involves attenuation of nicotinamide adenine dinucleo-
tide phosphate-oxidase-induced reactive oxygen species
production.24 It is noteworthy that FVB mice deficient in
Ang-(1–7) receptor exhibited changes in glucose and lipid
metabolism, which were manifested as a metabolic syndrome-
like state.25 These mice showed increased fasting plasma
glucose levels and moderate hypertension. Of particular
interest is a study by Pinheiro et al.26 showing that genetic
deletion of the Ang-(1–7) receptor in C57BL/6 mice resulted
in morphological alterations in the kidney. A reduction in
glomerular tuft diameter and increased expression of collagen
III, IV, and fibronectin in the kidney interstitium were
reported.26 Collagen IV and fibronectin also increased in the
mesangium. Blood pressure and plasma glucose levels were
unaffected, which is in contrast to findings from FVB mice
deficient in the Ang-(1–7) receptor.26
ACE2 may also have a role in disease progression in a
nondiabetic mouse model of early chronic kidney disease.
Dilauro et al.27 observed that kidney ACE2 was down-
regulated, but a significant increase in Ang II and consequent
albuminuria was perceived only after treatment with an
ACE2 inhibitor, MLN-4760. Administration of losartan
completely reversed this effect, suggesting an AT1 receptor-
dependent pathway, which is in accordance with our findings
from diabetic models of kidney disease.8,28
Overall, it appears that Ang-(1–7) may have some reno-
protective properties as aforementioned. Alternatively, it has
been postulated that the Ang-(1–7) receptor may have a role
in modulating the activity of the Ang II receptor.26,29 As
suggested by Kostenis et al.,29 Mas can function as a
physiological antagonist and inhibit the actions of Ang II by
forming a hetero-oligomer complex with the AT1 receptor.
Despite the emerging evidence of biological actions of Ang-
(1–7), it appears that under conditions of normal renin-
angiotensin system (RAS) activity, its role is limited. However,
when intrarenal RAS activity increases in pathophysiological
states, Ang-(1–7) may assume an important role as a vasodi-
lator. We favor the view that the dominant mechanism of the
effects of hrACE2 on blood pressure is its capacity to degrade
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Figure 3 | Effects of human recombinant ACE2 (hrACE2) on
angiotensin II (Ang II) and Ang-(1–7) and systolic blood
pressure (SBP). Plasma Ang II (a) and plasma Ang-(1–7) levels (b)
measured 5min after administration of Ang II bolus to mice
pretreated with either phosphate-buffered saline (PBS) or hrACE2.
The administration of Ang II alone (n¼ 8) in mice pretreated with
hrACE2 was associated with markedly lower plasma Ang II levels
and significantly increased plasma Ang-(1–7) levels as compared
with mice pretreated with PBS (n¼ 7). Injection of Ang II along
with A779 (n¼ 8) to mice pretreated with hrACE2 resulted in a
similar reduction in plasma Ang II and an increase in Ang-(1–7)
levels; ***Po0.001, *Po0.05 vs. Ang II only (reprinted from
Wysocki et al.22 with permission). (c) The concurrent changes on
blood pressure at 5min. It can be seen that blood pressure is
much lower when hrACE2 was infused with Ang II than when
Ang II was infused alone. The lower blood pressure with hrACE2
was seen in the presence and in the absence of A779. SBP data
also from the same study reported in Wysocki et al.22 but data not
originally displayed in this publication. SBP, systolic blood
pressure.
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Ang II. We cannot rule out, however, important effects of
Ang-(1–7) under other circumstances of blood pressure
control and chronic disease states in which it may have
important anti-fibrotic actions.30
LOCALIZATION OF ACE2 WITHIN THE NORMAL KIDNEY
In mouse kidney, ACE2 is highly expressed.8,15 Wysocki
et al.16 used a fluorogenic assay to observe that the activity of
ACE2 was about 20-fold higher in mouse kidney cortex than
in mouse heart tissue. In rat kidney, mRNA for ACE2 has
been detected in all nephron segments, except for the thick
ascending limb of the Loop of Henle, with increased
expression in the proximal tubule and the inner medullary
collecting ducts, as well as in vasae rectae.31 In mouse kidney,
ACE and ACE2 have been colocalized by confocal microscopy
in the brush border of proximal tubules (Figure 4).8 In a
renal MDCK cell line, ACE2 trafficking to the apical
membrane has been demonstrated, whereas ACE is targeted
to both the basolateral and apical portions of the cell
membrane.32 The fact that ACE and ACE2 may undergo
differential trafficking in proximal tubular cells is also
supported by a recent finding in conditionally megalin-
deficient mice.33 ACE staining was weaker in brush border
membranes of megalin-deficient proximal tubular cells. By
contrast, a markedly stronger staining for ACE2 was observed
in megalin-deficient as compared with megalin-positive
cell populations. This suggests that megalin or pathways
mediated by it may exert different or even opposite effects on
ACE and ACE2 surface expression in proximal tubular cells.33
In the mouse glomeruli, ACE and ACE2 are localized in
distinct cell types (Figure 4).8 ACE2 is present in glomerular
parietal and visceral epithelial cells (podocytes) and, to a
lesser extent, in glomerular mesangial cells.8 ACE is localized
only in glomerular endothelial cells.8
In human kidneys, the pattern of ACE2 expression is
similar to that of mouse kidneys.8,34 In kidneys from healthy
control subjects, Lely et al.34 have found ACE2 expression in
tubular, glomerular visceral, and parietal epithelial cells. In
agreement with our findings in mice, these authors did not
find ACE2 expression in glomerular endothelium.8,34 In
arterioles from mouse kidney, ACE2 predominantly coloca-
lizes with a-smooth muscle actin, a marker of smooth muscle
cells, but not with PECAM, an endothelial cell marker. This
was in sharp contrast to ACE, which strongly colocalizes with
PECAM but not with a-smooth muscle actin. These findings
show that in renal arterioles ACE2 is preferentially localized
in the vascular tunica media layer, whereas ACE is localized
in the endothelial layer.17
Consistent with animal studies, in humans the levels of
ACE2 are much higher in renal tubules than in glomer-
uli.8,15,35,36 In normal human kidney, ACE2 was also found
in vascular smooth muscle cells and the endothelium of
interlobular arteries.34 In a study examining rat kidneys,
however, ACE2 was predominantly found in glomeruli.37
This finding is surprising as it is in contrast with other studies
conducted using rat kidneys that found ACE2 mRNA
expression to be much higher in tubules as compared with
the glomerulus.31,35
ACE ACE2 Merge
ACE ACE2 Merge
Figure 4 |Angiotensin-converting enzyme (ACE) and ACE2 localization in the kidney. Immunofluorescence staining of ACE (a, left
panel, green) and ACE2 (a, medium panel, red) in proximal tubules. Merged images (a, right panel, yellow) show colocalization of ACE and
ACE2 at the apical site of proximal tubules. Immunofluorescence staining of ACE (b, left panel, green) and ACE2 (b, medium panel, red)
in a glomerulus from mouse kidney. Merging of both images shows essentially no colocalization of ACE and ACE2 in the glomerulus
(b, right panel; reprint from Ye et al.8 with permission).
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KIDNEY INJURY AFTER GENETIC AND PHARMACOLOGICAL
ACE2 ABLATION
Studies on kidneys from animals with ACE2 genetic ablation
have shown the development of glomerular lesions in aging
male mice.38 The kidneys of young (3-month-old) male
ACE2 mutant (ace2/y) mice showed no evidence of gross
glomerular abnormalities. By electron microscopy, evidence
of mesangial injury with small foci of fibrillar collagen
deposition was found.38 The early accumulation of fibrillar
collagen in glomerular mesangium was followed by develop-
ment of glomerulosclerosis by 12 months of age. These
changes in the glomeruli of aging male ACE2 mutant mice
were prevented by treatment with the Ang II type-1 receptor
antagonist irbesartan.38 This study showed that in aging male
mice, the absolute deficiency of ACE2 may lead to glomerular
disease. In contrast, we found no evidence of glomerular
pathology in an ACE2KO on the C57BL/6 background,
possibly because of the known resistance of this background
to the development of kidney disease.39
The effect of chronic administration of a specific ACE2
inhibitor, MLN-4760, on albumin excretion was studied in
two mouse models of diabetes.8,28,40 The administration of
MLN-4760 for 16 weeks resulted in worsening of albuminuria
in the db/db mice, and this was associated with increased
glomerular expression of fibronectin.8 The concomitant
administration of telmisartan, a specific AT1 receptor blocker,
completely prevented the worsening of albuminuria caused by
the ACE2 inhibitor.8 This suggested that the effects of ACE2
inhibitor were not nonspecific but rather were mediated by
enhanced Ang II acting on the AT1 receptor.8 In STZ-treated
mice, worsening of albuminuria after MLN-4760 administra-
tion was also found.28 Interestingly, the expression of ACE was
increased in the glomerulus and renal vasculature (but not in
the tubules) from STZ-treated mice, and was further
increased after MLN-4760 administration.28 On the basis of
these findings, we have proposed that there is a dual
mechanism of RAS activation in the glomerulus and renal
vasculature during chronic ACE2 inhibition: decreased
degradation of Ang II as a result of ACE2 downregulation,
and enhanced formation of Ang II as a result of increased ACE
activity.28 This would be a dreaded combination; in that, it
promotes glomerular Ang II accumulation via enhanced
formation and decreased degradation. In keeping with these
findings, Tikellis et al.40 using STZ model of diabetes in
C57BL/6 mice also reported that administration of an ACE2
inhibitor caused worsening of albuminuria, which was
associated with an increase in blood pressure.
In agreement with the studies using pharmacological
ACE2 inhibitor in diabetic mice, the deletion of the Ace2 gene
was recently found to accentuate diabetes-related glomerular
damage.41 In this study, Ace2 knockout mice were crossed
with Akita mice, a model of type 1 diabetes mellitus, and
exhibited a twofold increase in urinary albumin excretion.
Increased mesangial matrix scores and glomerular basement
membrane thicknesses in Ace2-/yIns2WT/C96Y mice were
accompanied by increased fibronectin and a-smooth muscle
actin staining in the glomeruli. Although kidney levels of Ang
II were not increased in the diabetic mice, treatment with an
Ang II receptor blocker reduced urinary albumin excretion
rate in Ace2-/yIns2WT/C96Y mice, suggesting that accelera-
tion of glomerular injury in these mice was Ang II
mediated.41
KIDNEY ACE2 IN DIABETIC KIDNEY DISEASE
In kidney cortex from db/db mice and STZ diabetic mice, ACE
was decreased markedly, whereas ACE2 was increased.15 The
differences in both enzymes were found at the protein level
and in changes in enzymatic activity.16 Others have previously
found a decrease in cortical ACE protein expression in the rat
STZ model of diabetic kidney disease.35,42
In mouse glomeruli, ACE and ACE2 expression assessed by
immunostaining have a divergent pattern. In the db/db mice,
ACE expression is increased, whereas ACE2 is decreased at
8 weeks of age when glomerular lesions are barely detectable
(Figure 5).8 This abnormal pattern is also found at 32 weeks
of age when glomerular lesions are fully established.43 An
increase in ACE was also found in glomeruli from STZ
diabetic rats.44 These findings in mice have been replicated in
humans with diabetic nephropathy associated with type 2
diabetes (see below).36 Another study in STZ diabetic rats
found a decrease in glomerular ACE2 activity accompanied by
a local increase in Ang and Ang II levels.45 Although in the
obese Zucker diabetic rat glomerular ACE2 was found to be
unchanged in comparison with lean controls,45 the majority
of animal studies indicate that diabetes is associated with
downregulation of ACE2 in the glomeruli.
When normal and diseased human kidney were com-
pared, the distribution of ACE2 appeared to be different.34
Under pathological conditions, ACE2 seems to emerge in
new locations within the kidney, such as the glomerular and
peritubular capillary endothelium.34 The neo-expression of
ACE2 in these sites was observed independently of the
etiology, both in primary and secondary renal diseases, as
well as in renal transplants.34
To assess whether variations within the ACE2 gene are
associated with diabetic nephropathy, Fro¨jdo¨ et al.47 analyzed
ACE2 gene polymorphisms in Finnish type 1 diabetic
patients.46 These authors found no association between
ACE2 gene polymorphisms and diabetic nephropathy. Similar
findings were reported in a study of type 1 diabetic patients of
British descent. ACE2 polymorphisms were not associated
with risk factors for this diabetic complication, such as blood
pressure, body mass index, or hemoglobin A1c.46 One
explanation is that the regulatory elements are located at a
long distance upstream or downstream of the transcription
unit.46 Alternatively, there could be a link between diabetic
nephropathy and genetic variability in the transcription factors
associated with ACE2 rather than in ACE2 itself.46 Another
possibility is that changes in ACE2 expression could manifest
only when kidney disease develops.46 From animal studies it is
known that proteinuria, hypertension, or treatment (i.e., AT1
receptor blocker or ACE inhibitor) may be associated with
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alterations in renal ACE2 expression.18,48–49 In humans, kidney
biopsy specimens often originate from patients having renal
or systemic disease secondary to diabetes and/or being on
medication. Therefore, it is possible that some findings on
ACE2 in human kidneys may reflect only the effect of diabetes
but could be related to other confounding variables.
This lack of association with ACE2 gene expression or
ACE2 gene polymorphisms may also be related to possible
posttranscriptional modifications of ACE2. For instance,
ACE2 has been shown to be increased at the protein level but
not at the mRNA level in renal tubules from db/db mice.16
Moreover, Tikellis et al.40 also recently found a discrepancy
between increased ACE2 activity and decreased ACE2 mRNA
levels in kidney cortex from STZ-induced diabetic mice.40
Taking these results together, it seems that the characteriza-
tion of ACE2 expression in diabetic kidney disease should
include studies at the protein and enzymatic activity levels.
In renal biopsies from humans with type 2 diabetes, the
expression of ACE2 and ACE was examined at the mRNA
level and compared with nondiabetic patients with various
kidney diseases. Although no significant alteration was found
with respect to ACE2 mRNA expression, a significant
upregulation was observed for ACE gene in diabetic renal
tissue.50 In this study, both diabetic and nondiabetic groups
had chronic kidney disease. A more recent cross-sectional
study examined ACE2 expression not only at the mRNA but
also at the protein level using kidney biopsies from 20
patients with type 2 diabetes and overt nephropathy.35 The
findings were compared with kidney tissue from 20 healthy
kidney transplant donors. The diabetic group examined was
homogenous with respect to several clinicopathological para-
meters, such as age, the presence of proteinuria, duration of
diabetes, and histological evidence of diabetic nephropathy.36
Using immunohistochemistry and in situ hybridization, the
authors assessed ACE and ACE2 in the tubulointerstitium
and in the glomeruli.36 ACE protein was significantly higher
in the tubulointerstitium and in glomeruli of patients with
diabetes than in healthy controls. Conversely, ACE2 protein
staining was decreased both in the tubulointerstitium and
glomeruli from diabetic patients. ACE2 mRNA expression in
those two compartments was also lower in diabetic subjects
when compared with controls.36
These findings are in agreement with another renal biopsy
study performed in patients with kidney disease due to type 2
diabetes,51 and are also congruent with our data in diabetic
mice regarding glomerular ACE and ACE2 expression.8 How-
ever, they differ in that in mouse kidney cortex and isolated
tubules ACE is decreased, whereas ACE2 is increased.8,15,16 It
is possible that this reflects a different stage of the disease and
the relative sparing of tubulointerstitial damage in the db/db
model of diabetes. Conceivably, decreased ACE and increased
ACE2 in the tubulointerstitium may exert a renoprotective
effect early on.15 Alternatively, the changes in ACE and ACE2
at the tubular level may be related to the severe hyperglycemia
and glycosuria in mice,16 which is usually not seen in humans
because of treatment with insulin.
In summary, both ACE and ACE2 are often found to be
abnormally expressed in kidneys from rodents with experi-
mental diabetes and humans with type 2 diabetes. It is
important to note that these differences may not affect
glomeruli and tubular structures in the same manner. So far,
the data are generally concordant; in that, ACE and ACE2 go
in opposite directions, and that at the glomerular level there
is an increase in ACE but a decrease in ACE2 in diabetic mice.
Overall, studies using kidney biopsies from patients with
type 2 diabetes have similarly shown that ACE is increased
whereas ACE2 is decreased at the glomerular level.
FUTURE PERSPECTIVES: ACE2 AS A THERAPEUTIC AND
DIAGNOSTIC TARGET
The therapeutic potential of amplifying ACE2 activity is
worthy of intensive investigation either as a primary therapy
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Figure 5 |Glomerular angiotensin-converting enzyme 2 (ACE2) and ACE in diabetic mice. (Left) Immunohistochemistry of ACE
(a,b) and ACE2 (c,d) in kidney sections from db/m (a,c) and db/db mice (b,d) showing an example of glomerular ACE and ACE2 staining. In
db/db mice, ACE staining within glomerular tuft (b, wide arrow) is more intense than in nondiabetic db/m controls (a, wide arrow). Unlike
glomeruli, proximal tubules from db/db mice have less staining for ACE (b, narrow arrow) than proximal tubules from db/m controls
(a, narrow arrow). The reverse pattern is seen for ACE2 staining within glomeruli, where ACE2 staining is less pronounced in diabetic mice
(d, wide arrow) than in controls (c, wide arrow), whereas proximal tubular staining is stronger in db/db than in db/m mice (c and d, single
narrow arrow). ACE2 staining in glomerular parietal epithelium also is shown (d, double arrows). (Right) Strong ACE staining is markedly
increased in glomeruli from diabetic mice in comparison with controls, whereas ACE2 is significantly decreased (reprint from Ye et al.8 with
permission).
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within the RAS or as a complement to existing ones.52 ACE2
deficiency has been associated with enhanced expression of
inflammatory markers,53 increased oxidative stress,38,54 and
may be proatherogenic.53,55 Many of these actions are likely
related to the local accumulation of Ang II. Much of the
expected therapeutic benefit of ACE2 amplification stems
from its ability to lower the levels of Ang II while
concomitantly increasing the formation of Ang-(1–7). The
relative contributions of the changes in these peptides have
been discussed and may vary from one indication to another.
For instance, in treating Ang-II-dependent forms of hyper-
tension, the benefit of ACE2 amplification seems clearly the
result of lowering the levels of Ang II and not of increasing
Ang-(1–7).22 A study in male Akita mice, a model of type 1
diabetes, showed that administration of hrACE2 could slow
the progression of diabetic nephropathy.56 In particular,
treatment with hrACE2 reduced albuminuria, mild hyperten-
sion, plasma Ang II levels, nicotinamide adenine dinucleotide
phosphate oxidase activation, glomerular hypertrophy, and
mesangial matrix expansion seen in these mice.56 It was
postulated that the protective effects of hrACE2 were
mediated by an increase in Ang-(1–7) levels in addition to
a decline in Ang II.56 Liu et al.57 conducted an interesting
study in which STZ-induced diabetic rats were given either
the ACE inhibitor benazepril, an adenoviral (Ad)-ACE2
injection, or both for 4 weeks. Their results suggested that
although both ACE inhibition and ACE2 overexpression help
improve signs of diabetic nephropathy, one was not more
effective than the other. There is a need for much more
evidence showing that ACE2 amplification in itself can
provide organ protection beyond what is already achieved by
current blockers of the RAS. One question that needs to be
addressed is the role of ACE2 in the face of blockade of the
RAS such as ACE inhibition or AT1 receptor blockade. It
should be noted that with both therapies Ang II levels might
not be reduced, whereas direct renin inhibition may suppress
Ang II more efficiently. In the case of ACE inhibition, Ang II
levels reduce transiently and then return to normal as a result
of the well-known ACE escape phenomenon. In the case of
Ang II blockers, the levels of Ang II increase when the AT1
receptor is blocked. Thus, with both ACE inhibitors and
AT1 receptor blockers, there is clearly incomplete suppression
of Ang II. Although this does not appear to negate their
antihypertensive and renoprotective effects, it is possible that
combining these therapies with ACE2 amplification therapy
could be very effective by fostering the degradation of Ang II
and thereby providing a more complete level of RAS down-
regulation. It should be noted, however, that this theoretical
advantage currently lacks direct evidence, and therefore the
potential therapeutic effect of ACE2 amplification alone or in
combination remains speculative at present.
Agents that increase ACE2 activity at the tissue level may
be suitable for chronic therapy of a condition such as diabetic
nephropathy. Currently, there is limited information on
potential agonists on ACE2 activity such as XNT.58 Their
potency in increasing ACE2 activity is quite weak (Ye et al.,
unpublished 2010). Conversely, the administration of
hrACE2 results in a robust increase in circulating plasma
ACE2 activity but does not increase tissue ACE2 activity.22
In a search for markers of progression of diabetic kidney
disease, urine is an interesting source, as it is readily collected
and available. In diabetic mice, urine ACE2 activity is
high, suggesting that it may be a biomarker of diabetic
kidney disease.59 Wang et al.60 examined urinary ACE2 mRNA
expression in patients with type 2 diabetes in context of
diabetic nephropathy development. The authors found that
there was a positive relationship between urinary ACE2 mRNA
expression and the degree of proteinuria. Taking into account
the possibility of posttranscriptional regulation of ACE2,
longitudinal studies analyzing urinary ACE2 protein expres-
sion and/or enzymatic activity may shed some light onto the
question whether ACE2 could have a predictive value for
diabetic nephropathy.59 One must take into account, however,
that the final urine does not reflect necessarily the site of the
nephron where alterations in ACE and ACE2 reside. This is
particularly important because of the dissociation between
tubular and glomerular ACE2 noted in diabetes models.8
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